Eupraxia Pharmaceuticals Inc.
EPRXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. With a market capitalization of $430.5M, it sits in small-cap territory. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Market Cap
$430.5M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-7.32
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.90
ROE
-54.5%
ROA
-33.8%
Cash
$138.9M
Total Debt
$2.0M
Free CF
-$17.6M
52W Change
24.6%
Annual Financials
Cash vs Debt
With $138.9M in cash and $2.0M in debt, EPRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$17.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -54.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, EPRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Eupraxia Pharmaceuticals Inc.'s trajectory.